Kintara Therapeutics
Biotechnology, 4747 Executive Dr, San Diego, California, 92121, United States, 11-50 Employees
Phone Number: 85********
Who is KINTARA THERAPEUTICS
Our Fight Against Cancer Kintara Therapeutics is dedicated to the development of novel cancer therapies for patients with unmet medical needs. Kintara Therapeutics has teamed up with outs...
Read More
-
Headquarters: 4747 Executive Dr, San Diego, California, 92121, United States
-
Employees: 11-50
-
Revenue: $1 Million to $5 Million
Industry: Biotechnology
SIC Code: 2834
Does something look wrong? Fix it. | View contact records from KINTARA THERAPEUTICS
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Kintara Therapeutics
Answer: Kintara Therapeutics's headquarters are located at 4747 Executive Dr, San Diego, California, 92121, United States
Answer: Kintara Therapeutics's phone number is 85********
Answer: Kintara Therapeutics's official website is https://kintara.com
Answer: Kintara Therapeutics's revenue is $1 Million to $5 Million
Answer: Kintara Therapeutics's SIC: 2834
Answer: Kintara Therapeutics has 11-50 employees
Answer: Kintara Therapeutics is in Biotechnology
Answer: Kintara Therapeutics contact info: Phone number: 85******** Website: https://kintara.com
Answer: Our Fight Against Cancer Kintara Therapeutics is dedicated to the development of novel cancer therapies for patients with unmet medical needs. Kintara Therapeutics has teamed up with outstanding academic and clinical research institutions from around the world to support the development of our novel cancer therapies. A Pipeline of Breakthrough Cancer Therapeutics VAL-083 is a first-in-class small molecule DNA-targeting agent that exhibits a novel mechanism of action that results in DNA double strand breaks and cancer cell death. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types. VAL-083's indications include: Glioblastoma Multiforme (GBM) Ovarian Cancer Pediatric CNS Tumors REM-001 is a second generation photosensitizer drug possessing multiple advantages over earlier generation PDT compounds. REM-001s indications include: Cutaneous Metastatic Breast Cancer Recurrent Basal Cell Carcinoma Nevus Syndrome Hemodialysis Arteriovenous (AV) Access
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Powered by
Sign in to CIENCE GO Data to uncover contact details
Free credits every month